Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC)

The Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC) will take place from November 8-12 in Boston, Massachusetts

Cellectis will present pre-clinical data on TALEN®-edited smart CAR T-cells to overcome key challenges of targeting solid tumors in two poster presentations.

Poster presentation:
Cellectis will present a poster on TALEN®-edited smart CAR T-cells targeting MUC1- expressing solid tumors. MUC1 is a tumor-associated antigen that is overexpressed in triple-negative breast cancer (TNBC) and other solid tumor malignancies.

Title: Multi-armored allogeneic MUC-1 CAR T-cells efficiently control triple negative breast cancer tumor growth
Poster Number: 217
Presenter: Piril, Erler Ph.D., Scientist II, Immuno-Oncology, Cellectis
Date/Time: Thursday, November 10th, posters will be on display from 9:00 AM- 9:00 PM, Hall C

Poster presentation:
Cellectis will present a poster on innovative T-cell engineering strategies designed to increase the activity of CAR T-cells for solid tumors while mitigating toxicity risk.

Title: TALEN®-edited smart CAR T-cells leverage solid tumor microenvironment for specific and effective immunotherapy
Poster Number: 325
Presenter: Shipra Das Ph.D., Senior Scientist & Team Leader Immuno-Oncology, Cellectis
Date/Time: Thursday, November 10th, posters will be on display from 9:00 AM- 9:00 PM, Hall C

Full text of the abstracts will be released on the SITC website at 8:00 a.m. EST on November 7, 2022.